Join Growin Stock Community!

Boston scientific corporationBSX.US Overview

US StockHealthcare
(No presentation for BSX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BSX AI Insights

BSX Overall Performance

BSX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BSX Recent Performance

-1.83%

Boston scientific corporation

0.05%

Avg of Sector

-0.31%

S&P500

BSX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BSX Key Information

BSX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BSX Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Price of BSX

BSX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BSX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.95
PE Ratio (TTM)
39.61
Forward PE
23.24
PS Ratio (TTM)
5.68
PB Ratio
4.64
Price-to-FCF
30.60
METRIC
VALUE
vs. INDUSTRY
Gross Margin
69.01%
Net Margin
14.44%
Revenue Growth (YoY)
19.88%
Profit Growth (YoY)
20.58%
3-Year Revenue Growth
17.70%
3-Year Profit Growth
18.13%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.95
PE Ratio (TTM)
39.61
Forward PE
23.24
PS Ratio (TTM)
5.68
PB Ratio
4.64
Price-to-FCF
30.60
Gross Margin
69.01%
Net Margin
14.44%
Revenue Growth (YoY)
19.88%
Profit Growth (YoY)
20.58%
3-Year Revenue Growth
17.70%
3-Year Profit Growth
18.13%

  • When is BSX's latest earnings report released?

    The most recent financial report for Boston scientific corporation (BSX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BSX's short-term business performance and financial health. For the latest updates on BSX's earnings releases, visit this page regularly.

  • Where does BSX fall in the P/E River chart?

    According to historical valuation range analysis, Boston scientific corporation (BSX)'s current price-to-earnings (P/E) ratio is 39.06, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of BSX?

    According to the latest financial report, Boston scientific corporation (BSX) reported an Operating Profit of 824M with an Operating Margin of 15.59% this period, representing a growth of 21.71% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BSX's revenue growth?

    In the latest financial report, Boston scientific corporation (BSX) announced revenue of 5.29B, with a Year-Over-Year growth rate of 15.9%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BSX have?

    As of the end of the reporting period, Boston scientific corporation (BSX) had total debt of 11.44B, with a debt ratio of 0.26. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BSX have?

    At the end of the period, Boston scientific corporation (BSX) held Total Cash and Cash Equivalents of 1.97B, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BSX go with three margins increasing?

    In the latest report, Boston scientific corporation (BSX) achieved the “three margins increasing” benchmark, with a gross margin of 69.6%%, operating margin of 15.59%%, and net margin of 12.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BSX's profit trajectory and future growth potential.

  • Is BSX's EPS continuing to grow?

    According to the past four quarterly reports, Boston scientific corporation (BSX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.46. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BSX?

    Boston scientific corporation (BSX)'s Free Cash Flow (FCF) for the period is 1.01B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 14.51% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BSX?

    The latest valuation data shows Boston scientific corporation (BSX) has a Price-To-Earnings (PE) ratio of 39.06 and a Price/Earnings-To-Growth (PEG) ratio of -4.5. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.